SCHEMBL20001034

SCHEMBL20001034

C[C@]1(CC(=O)Nc2nccs2)NCCc2cc(OCC3CCCO3)c(Oc3ccc(C(=O)O)cc3)cc21

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PCSK9 Q8NBP7 4/20 0.42
MAP1LC3B Q9GZQ8 4/20 0.42
KDM4E B2RXH2 4/20 0.39
NPC1 O15118 5/20 0.39
RAB9A P51151 5/20 0.39
SMN1; SMN2 Q16637 4/20 0.39
LMNA P02545 3/20 0.38
NPSR1 Q6W5P4 2/20 0.38
TSHR P16473 1/20 0.38
ALDH1A1 P00352 4/20 0.37
KMT2A Q03164 3/20 0.37
MEN1 O00255 2/20 0.37
TDP1 Q9NUW8 1/20 0.37
MAPT P10636 2/20 0.37
HPGD P15428 2/20 0.37
THRB P10828 1/20 0.37
HTT P42858 1/20 0.37
MAPK1 P28482 2/20 0.36
BRD4 O60885 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22697365 0.94 KDM4E (0.41) PCSK9MAP1LC3BKDM4ENPC1RAB9A
SCHEMBL30228396 0.92 PCSK9 (0.39) PCSK9MAP1LC3BKDM4ENPC1RAB9A
SCHEMBL19995763 0.92 PCSK9 (0.39) PCSK9MAP1LC3BKDM4ENPC1RAB9A
SCHEMBL20000922 0.91 PCSK9 (0.40) PCSK9MAP1LC3BKDM4ENPC1RAB9A
SCHEMBL30228456 0.89 PCSK9 (0.42) PCSK9MAP1LC3BKDM4ENPC1RAB9A
SCHEMBL19995766 0.89 PCSK9 (0.42) PCSK9MAP1LC3BKDM4ENPC1RAB9A
SCHEMBL20001155 0.88 PCSK9 (0.41) PCSK9MAP1LC3BKDM4ELMNANPSR1
SCHEMBL20001079 0.87 PCSK9 (0.40) PCSK9MAP1LC3BKDM4ENPC1RAB9A
SCHEMBL30228565 0.86 PCSK9 (0.42) PCSK9MAP1LC3BKDM4ELMNANPSR1
SCHEMBL19995720 0.86 PCSK9 (0.42) PCSK9MAP1LC3BKDM4ELMNANPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3515891-B1 SUBSTITUTED 1-METHYL-1,2,3,4-TETRAHYDROISOQUINOLINE MOLECULES AS PCSK9 ALLOSTERIC BINDERS MERCK SHARP & DOHME LLC (US) 2023-03-08 EP disclosed
US-11008313-B2 Substituted 1-methyl-1,2,3,4-tetrahydroisoquinoline molecules as PCSK9 allosteric binders MERCK SHARP & DOHME CORP. (US) 2021-05-18 US disclosed
US-11008313-B2 Substituted 1-methyl-1,2,3,4-tetrahydroisoquinoline molecules as PCSK9 allosteric binders MERCK SHARP & DOHME CORP. (US) 2021-05-18 US disclosed
US-20200369657-A1 SUBSTITUTED 1-METHYL-1,2,3,4-TETRAHYDROISOQUINOLINE MOLECULES AS PCSK9 ALLOSTERIC BINDERS MERCK SHARP & DOHME CORP. (US) 2020-11-26 US disclosed
US-20200369657-A1 SUBSTITUTED 1-METHYL-1,2,3,4-TETRAHYDROISOQUINOLINE MOLECULES AS PCSK9 ALLOSTERIC BINDERS MERCK SHARP & DOHME CORP. (US) 2020-11-26 US disclosed
WO-2018057409-A1 SUBSTITUTED 1-METHYL-1,2,3,4-TETRAHYDROISOQUINOLINE MOLECULES AS PCSK9 ALLOSTERIC BINDERS MERCK SHARP & DOHME CORP. (US) 2018-03-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200369657-A1 SUBSTITUTED 1-METHYL-1,2,3,4-TETRAHYDROISOQUINOLINE MOLECULES AS PCSK9 ALLOSTERIC BINDERS PCSK9, PCSK7, LDLR PCSK9 1/4885MAP1LC3B 2259/4885KDM4E 304/4885
US-11008313-B2 Substituted 1-methyl-1,2,3,4-tetrahydroisoquinoline molecules as PCSK9 allosteric binders PCSK9, PCSK7, LDLR PCSK9 1/4885MAP1LC3B 2190/4885KDM4E 305/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.